Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

On Windows 11, desktop elements like the Taskbar, Start menu, and certain apps, such as the Settings app, use a new transparent base layer featuring the Mica material from the Microsoft Fluent ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

The company also delayed its break-even timeline from 2026 to 2028. View of Moderna company office entrance exterior with logo sign in Cambridge, Massachusetts, June 14, 2024. Shares fell 19 ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

(Reuters) -Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its ...

REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO Moderna logo and stock graph are seen displayed in this illustration in May 2022. Moderna cut its 2025 sales forecast by $1 billion today, hurt by a slow ...

The US Department of Health and Human Services said on Friday it would award $306 million in funds to help bird flu monitoring, as the virus spreads in dairy herds and farm workers across the country.